Department of Biochemistry, Faculty of Medicine, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Thromb Res. 2012 Oct;130(4):661-6. doi: 10.1016/j.thromres.2011.11.035. Epub 2011 Dec 28.
Protein C inhibitor was purified from human plasma by use of a dermatan sulfate or heparin column, followed by hydroxyapatite, gel filtration and ion exchange columns. A dimer of protein C inhibitor was detected by SDS-PAGE under reducing conditions, in addition to two forms of monomer species. One of the monomers, 52-kDa PCI, formed a stable complex with activated protein C, urokinase, plasma and tissue kallikrein, but the dimer species and 48-kDa PCI were inactive. When the monomer and dimer forms of protein C inhibitor were applied to 2D-PAGE, more than 20 spots were observed by Western blot analysis and were confirmed to be protein C inhibitor by MALDI-TOF mass spectrometry. The heterogeneity of the protein C inhibitor species was not due to glycosylation or phosphorylation.
蛋白 C 抑制剂通过使用硫酸皮肤素或肝素柱、然后使用羟磷灰石、凝胶过滤和离子交换柱从人血浆中纯化得到。在还原条件下通过 SDS-PAGE 检测到蛋白 C 抑制剂的二聚体,除了两种单体形式之外。单体之一的 52-kDa PCI 与活化蛋白 C、尿激酶、血浆和组织激肽释放酶形成稳定的复合物,但二聚体形式和 48-kDa PCI 没有活性。当将蛋白 C 抑制剂的单体和二聚体形式应用于 2D-PAGE 时,通过 Western blot 分析观察到超过 20 个斑点,并通过 MALDI-TOF 质谱法确认为蛋白 C 抑制剂。蛋白 C 抑制剂的同种型的异质性不是由于糖基化或磷酸化引起的。